Association of British Clinicial Diabetologists

Autumn Meeting

BMA House, London

9^th & 10^th November 2017

POSTERS FOR ONLINE VIEWING

1            Day-to-day variability of fasting self-measured blood glucose associates with risk of hypoglycaemia in adults with type 1 and type 2 diabetes

Bailey TS (1), Bhargava A (2), DeVries JH (3), Gerety G (4), Gumprecht J (5), Lane W (6), Wysham CH (7), Bak BA (8), Hachmann-Nielsen E (9),  Walker M (10), Philis-Tsimikas A (11).

(1) AMCR Institute, Escondido, CA, USA

(2) Iowa Diabetes and Endocrinology Research Center, Des Moines, IA, USA

(3) University of Amsterdam, Amsterdam, The Netherlands

(4) Albany Medical Center, Albany, NY, USA

(5) Medical University of Silesia, Zabrze, Poland

(6) Mountain Diabetes and Endocrine Center, Asheville, NC, USA

(7) Rockwood Clinic, Spokane, WA, USA

(8) Novo Nordisk A/S, Søborg, Denmark

(9) Novo Nordisk A/S, Søborg, Denmark

(10) Novo Nordisk Ltd., West Sussex, UK

(11)Scripps Whittier Diabetes Institute, San Diego, CA, USA .

Click here to view poster

2            Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs. basal–bolus therapy in patients with type 2 diabetes: DUAL VII trial

Billings LK (1), Oviedo A (2), Rodbard HW (3), Tentolouris N (4), Grøn R (5), Halladin N (6), Walker M (7), Jódar E (8).

(1) NorthShore University HealthSystem, Evanston, IL; University of Chicago Pritzker School of Medicine, Chicago, IL, USA

(2) Santojanni Hospital and Cenudiab, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

(3) Endocrine and Metabolic Consultants, Rockville, MD, USA

(4) National and Kapodistrian University of Athens, Medical School, Athens, Greece

(5) Novo Nordisk A/S, Søborg, Denmark

(6) Novo Nordisk A/S, Søborg, Denmark

(7)Novo Nordisk Ltd., West Sussex, UK

(8) University Hospital Quiron Salud, Madrid, Spain

Click here to view poster

3            World travel with Type-1 diabetes

Alex Charlton A (1), Jessica Charlton J (1).

(1) University Hospitals of Leicester, Camp Charnwood

Click here to view poster

4            Longer acting basal insulin analogues ‘Toujeo’ and ‘Tresiba’ reduce treatment side effects; a therapeutic advance in selected patients

Koh WS (1), Shotliff K (1), Feher MD (1).

(1) Beta Cell Diabetes Centre, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK

Click here to view poster

5            Lower glucose variability and risk for hypoglycaemia on insulin Glargine 300 U/mL versus insulin Glargine 100 U/mL, evaluated by the low blood glucose index in randomized phase lll clinical crials

Kovatchev BP (1), Meng Z (2), Breton MD (3), Leroy B (4), Cali A (4).

(1) Center for Diabetes Technology, University of Virginia, Charlottesville, VA, US

(2) Sanofi, Bridgewater, NJ, USA

(3) Université de Sherbrooke, Sherbrooke, Canada

(4) Sanofi, Paris, France

Click here to view poster

6            Onset 1: efficacy and safety of mealtime fast‑acting insulin aspart versus insulin aspart after 52 weeks

Mathieu C (1), Bruce Bode B (2), Franek E (3), Philis-Tsimikas A (4), Rose L (5), Graungaard T (6), Østerskov AB (7), Azizuddin S (8), Russell-Jones D (9).

(1) UZ Leuven, Leuven, Belgium

(2) Atlanta Diabetes Associates, Atlanta, Georgia, USA

(3) Mossakowski Medical Research Center, Polish Academy of Sciences, Warsaw, Poland

(4) Scripps Whittier Diabetes Institute, San Diego, California, USA

(5) Diabetes Research Center, Münster, Germany

(6) Novo Nordisk A/S, Søborg, Denmark

(7) Novo Nordisk A/S, Søborg, Denmark

(8) Novo Nordisk Ltd., Gatwick, UK

(9) Royal Surrey County Hospital, Guildford, UK

Click here to view poster

7            Achievement of HbA1c targets in the diabetes unmet need with basal insulin Evaluation (DUNE) real-world study

Meneghini L (1,2), Mauricio D (3), Orsi E(4) , Cali A (5), Westerbacka J (5), Stella P (5), Candelas C (5), Pilorget V (5), Perfetti R (6), Khunti K (7).

(1) University of Texas Southwestern Medical Center, Dallas, TX, USA

(2) Parkland Health & Hospital System, Dallas, TX, USA

(3) Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

(4) Endocrine and Metabolic Diseases Unit, Fondazione Ca’ Granda IRCCS, Milan, Italy

(5) Sanofi, Paris, France

(6) Sanofi, Bridgewater, NJ, USA

(7) Diabetes Research Centre, University of Leicester, Leicester, UK

Click here to view poster

8            Cost-effectiveness of insulin GLARGINE 300 Units/ML (GLA-300) VS Insulin DEGLUDEC 100 Units/ML (IDEG) in T2D

Murphy DR (1), Yu X (1), Fournier M (2), Klein TM (1), Fan T (3), Perk S (1), Preblick R (3), Zhou FL (3)

(1) Medical DEecision Modelling INC., Indianapolis, IN, USA

(2) Sanofi, Chilly-Mazarin, France

(3) Sanofi US, INC., Bridgewater, NJ, USA

Click here to view poster

9            Modelling subcutaneous absorption of U100 and U300 insulin GLARGINE in type 1 diabetes

Schiavon M (1), Visentin R (1), Dalla Man C (1) Klabunde T (2), Cobelli C (1).

(1) Department of Information Engineering, University of Padova, Padova, Italy

(2) Sanofi-Aventis Deutschland GMBH, Translational Medicine & Early Development (TMED), Frankfurt, Germany

Click here to view poster

10            Clinical outcomes of patients with type 2 diabetes (T2D) who switched to insulin Glargine 300 U/ML (GLA-300) from insulin Glargine 100 U/ML (GLA-100) in real-world US treatment settings

Ye F(1), Zhou FL (1), Xie L (2),  Kariburyo F (2),  Meneghini LF (3).

(1) Sanofi US, INC., Bridgewater, NJ, USA

(2) Statinmed Research, Ann Arbor, MI, USA

(3) University of Texas Soutwestern Medical Center and Parkland Health & Hospital System, Dallas, TX, USA

Click here to view poster